Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.
An expert discusses how efficacy and safety data from trials such as METEOR, TIVO-3, TiNivo-2, and LITESPARK-005 guide third line (3L) renal cell carcinoma (RCC) treatment. Differences in trial populations, evolving long-term trends, and prior immune checkpoint inhibitor (ICI) use impact ...
A panelist discusses how, based on the NCCN guidelines for kidney cancer, third-line treatment options for this patient include cabozantinib, lenvatinib plus everolimus, tivozanib, and everolimus monotherapy. Clinical trials and best supportive care remain important considerations at this stage.
Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.
Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.
Renal cell carcinoma (RCC) is the 14 th most incident cancer worldwide, and no curative therapeutic options are available for advanced and metastatic disease...
Percutaneous ablation therapies currently play a major role in the management of T1a and T1b renal cell carcinoma (RCC). These therapies include thermal abla...
Kathryn E. Beckermann, MD, PhD, details the role of tivozanib as second- and third-line therapy in patients with locally advanced or metastatic ccRCC.
“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.”
... VHL is crippled. The team also found that the cancer cells break these viral proteins into fragments and present them on the cell surface as flags ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.